Horizon Pharma and Mundipharma in deal for Lodotra in Middle East and Africa

11 November 2013

USA-based Horizon Pharma (Nasdaq: HZNP) says its Swiss subsidiary has signed an exclusive agreement with privately-held Swiss drugmaker Mundipharma for the commercialization and distribution of Lodotra (prednisone) in the Middle East and African Region.

Lodotra, an innovative delayed-release formulation of prednisone specifically designed to deliver the active drug at the most physiologically efficient time, is approved in the USA under the trade name Rayos and in over 30 other countries to treat moderate to severe active rheumatoid arthritis (RA) when accompanied by morning stiffness.

"Mundipharma has a highly respected reputation through its product portfolio across multiple geographies, including Lodotra in Europe, and we are pleased to expand our existing agreement with them to commercialize Lodotra in these additional territories," said Todd Smith, executive vice president, chief commercial officer, Horizon.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >